List of patents in the Autoimmune disease industry

Patents where

Current Assignee

Industry

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11344565 Methods for the preparation of ribosides	Patent 11344565 was granted and assigned to Gilead Sciences on May, 2022 by the United States Patent and Trademark Office.	Gilead Sciences	Gilead Sciences	United States Patent and Trademark Office	11344565	May 31, 2022
‌ US Patent 7582631 Substituted heterocyclic compounds and methods of use	Patent 7582631 was granted and assigned to Amgen on September, 2009 by the United States Patent and Trademark Office.		Amgen	United States Patent and Trademark Office	7582631	September 1, 2009
‌ US Patent 9517264 Human FGF receptor and β-Klotho binding proteins	Patent 9517264 was granted and assigned to Amgen on December, 2016 by the United States Patent and Trademark Office.		Amgen	United States Patent and Trademark Office	9517264	December 13, 2016
‌ US Patent 11607451 Self-buffering antibody formulations	Patent 11607451 was granted and assigned to Amgen on March, 2023 by the United States Patent and Trademark Office.	Amgen	Amgen	United States Patent and Trademark Office	11607451	March 21, 2023
‌ US Patent 7833979 Toxin peptide therapeutic agents	Patent 7833979 was granted and assigned to Amgen on November, 2010 by the United States Patent and Trademark Office.		Amgen	United States Patent and Trademark Office	7833979	November 16, 2010
‌ US Patent 10569014 Device and method for making aseptic connections	Patent 10569014 was granted and assigned to Amgen on February, 2020 by the United States Patent and Trademark Office.	Amgen	Amgen	United States Patent and Trademark Office	10569014	February 25, 2020
‌ US Patent 11773106 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Patent 11773106 was granted and assigned to AbbVie Inc. on October, 2023 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	11773106	October 3, 2023
‌ US Patent 11780848 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof	Patent 11780848 was granted and assigned to AbbVie Inc. on October, 2023 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	11780848	October 10, 2023
‌ US Patent 10308644 Heterocyclic compounds as immunomodulators	Patent 10308644 was granted and assigned to Incyte on June, 2019 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	10308644	June 4, 2019
‌ US Patent 9061097 Drug delivery device	Patent 9061097 was granted and assigned to Amgen on June, 2015 by the United States Patent and Trademark Office.		Amgen	United States Patent and Trademark Office	9061097	June 23, 2015
‌ US Patent 10492990 Drug cassette, autoinjector, and autoinjector system	Patent 10492990 was granted and assigned to Amgen on December, 2019 by the United States Patent and Trademark Office.	Amgen	Amgen	United States Patent and Trademark Office	10492990	December 3, 2019
‌ US Patent 11479593 Compositions, formulations and interleukin production and purification		Applied Molecular Transport	Applied Molecular Transport	United States Patent and Trademark Office	11479593	October 25, 2022
‌ US Patent 8119631 Inhibitors of interleukin-1β converting enzyme	Patent 8119631 was granted and assigned to Vertex Pharmaceuticals on February, 2012 by the United States Patent and Trademark Office.		Vertex Pharmaceuticals	United States Patent and Trademark Office	8119631	February 21, 2012
‌ US Patent 11020537 Drug cassette, autoinjector, and autoinjector system	Patent 11020537 was granted and assigned to Amgen on June, 2021 by the United States Patent and Trademark Office.	Amgen	Amgen	United States Patent and Trademark Office	11020537	June 1, 2021
‌ US Patent 7820671 Peptidomimetic protease inhibitors	Patent 7820671 was granted and assigned to Vertex Pharmaceuticals on October, 2010 by the United States Patent and Trademark Office.		Vertex Pharmaceuticals	United States Patent and Trademark Office	7820671	October 26, 2010
‌ US Patent 11459377 Synthetic library of specific binding molecules		‌ Elasmogen Limited	‌ Elasmogen Limited	United States Patent and Trademark Office	11459377	October 4, 2022
‌ US Patent 7919498 Substituted pyrazolo[3,4-d]pyrimidines as PI3K inhibitors	Patent 7919498 was granted and assigned to Amgen on April, 2011 by the United States Patent and Trademark Office.		Amgen	United States Patent and Trademark Office	7919498	April 5, 2011
‌ US Patent 11866434 Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof	Patent 11866434 was granted and assigned to Incyte on January, 2024 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11866434	January 9, 2024
‌ US Patent 11583536 Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use	Patent 11583536 was granted and assigned to Celgene on February, 2023 by the United States Patent and Trademark Office.	Celgene	Celgene	United States Patent and Trademark Office	11583536	February 21, 2023
‌ US Patent 11878149 Drug delivery device	Patent 11878149 was granted and assigned to Amgen on January, 2024 by the United States Patent and Trademark Office.	Amgen	Amgen	United States Patent and Trademark Office	11878149	January 23, 2024
‌ US Patent 11767326 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Patent 11767326 was granted and assigned to AbbVie Inc. on September, 2023 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	11767326	September 26, 2023
‌ US Patent 9873894 Methods and compositions for treatment of a genetic condition	Patent 9873894 was granted and assigned to Sangamo Therapeutics on January, 2018 by the United States Patent and Trademark Office.		Sangamo Therapeutics	United States Patent and Trademark Office	9873894	January 23, 2018
‌ US Patent 8252923 Peptidomimetic protease inhibitors	Patent 8252923 was granted and assigned to Vertex Pharmaceuticals on August, 2012 by the United States Patent and Trademark Office.		Vertex Pharmaceuticals	United States Patent and Trademark Office	8252923	August 28, 2012
‌ US Patent 7442778 Modified Fc molecules	Patent 7442778 was granted and assigned to Amgen on October, 2008 by the United States Patent and Trademark Office.		Amgen	United States Patent and Trademark Office	7442778	October 28, 2008
‌ US Patent 11976077 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms therof	Patent 11976077 was granted and assigned to AbbVie Inc. on May, 2024 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	11976077	May 7, 2024

...

Results per page:

5,561 results

0 selected

5,561 results

0 selected